Ropes & Gray Advised Bain Capital on Creation of a New Company Dedicated to Developing Innovative Immunology Therapies

Ropes & Gray advised Bain Capital on the creation of a new biopharmaceutical company focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launched with five immunology assets in-licensed from Bristol Myers Squibb and a $300 million financing commitment that was led by Bain Capital. The launch of the new company was announced in a July 28 press release.

Founded in 1984, Bain Capital is a global private investment firm with 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management.

The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor, life sciences transactions counsel Ray Grant and life sciences licensing associate Evan Tallmadge.

The team also included life sciences transactions partner Arthur Mok, private equity partner Bill Mone, tax partner Pamela Glazier, executive compensation & employee benefits partners Kyle Higley and Megan Bisk and antitrust partner Lisa Kaltenbrunner.